SEC Filing Summary: AcelRx Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on August 31, 2012. The report serves as a current disclosure regarding legal opinions related to a pending securities offering.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing and does not contain financial statements or performance data.
Material Changes
There are no material changes to financial performance or operations reported in this filing. The document solely addresses the submission of a legal opinion regarding the Company's Registration Statement on Form S-3 (File No. 333-183237) and a related prospectus supplement filed on August 31, 2012.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The primary purpose is to satisfy disclosure requirements by attaching the legal opinion of Cooley LLP (Exhibit 5.1) concerning the legality of the shares of Common Stock to be offered and sold.
Key Facts for Investor Verification
- Verify the status of the Form S-3 Registration Statement (File No. 333-183237) filed on August 10, 2012.
- Review the attached legal opinion from Cooley LLP regarding the validity of the stock offering.
- Confirm the details of the prospectus supplement filed on August 31, 2012.
- Note that this filing contains no financial performance data; refer to recent 10-Q or 10-K filings for financial metrics.